Heterotopic heart transplantation: where do we stand?

被引:10
|
作者
Flecher, Erwan [1 ]
Fouquet, Olivier [2 ]
Ruggieri, Vito Giovanni [1 ]
Chabanne, Celine [1 ]
Lelong, Bernard [1 ]
Leguerrier, Alain [1 ]
机构
[1] Rennes Univ Hosp, Dept Cardiothorac & Vasc Surg, Rennes, France
[2] Angers Univ Hosp, Dept Cardiac Surg, Angers, France
关键词
Heterotopic; Orthotopic; Transplantation; FIXED PULMONARY-HYPERTENSION; CIRCULATORY SUPPORT; HEMODYNAMICS; PIONEER;
D O I
10.1093/ejcts/ezt136
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Orthotopic heart transplantation (OHT) is a well established and commonly utilized procedure for end-stage heart failure patients. Heterotopic heart transplantation (HHT) is a surgical procedure that allows the graft to be connected to the native heart in a parallel fashion. The main advantage of HHT is to assist the patient's native heart and to maintain circulation in the cases of severe acute rejection. HHT has also been proposed to overcome pulmonary hypertension, to increase the size of the donor pool and to decrease waiting times without increasing morbidity caused by the procedure. However, only a few papers have reported the short- or long-term results of HHT, and most of these studies have included <30 cases. OHT remains the standard technique and is preferable whenever the patient meets the current criteria and a suitable organ is available. HHT is far less useful than in the past because of the major advances in immunosuppression therapy and the development of long-term mechanical circulatory support. This study reviews the origin of HHT and discusses clinical developments, including their advantages and disadvantages.
引用
收藏
页码:201 / 206
页数:6
相关论文
共 50 条
  • [1] Uterus transplantation:: where do we stand today and where should we go?
    Brannstrom, Mats
    Wranning, Caiza Almen
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (04) : 427 - 429
  • [2] Transplantation tolerance: the big picture. Where do we stand, where should we go?
    Waldmann, H.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2017, 189 (02) : 135 - 137
  • [3] Tolerogenic Dendritic Cells in Solid Organ Transplantation: Where Do We Stand?
    Marin, Eros
    Cuturi, Maria Cristina
    Moreau, Aurelie
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [4] The European registry: Where do we stand?
    Jager, KJ
    van Dijk, PCW
    Dekker, FW
    Cornet, R
    Krediet, RT
    Briggs, JD
    PERITONEAL DIALYSIS INTERNATIONAL, 2000, 20 : S118 - S120
  • [5] Pathogenesis of non-HLA antibodies in solid organ transplantation: Where do we stand?
    Delville, Marianne
    Charreau, Beatrice
    Rabant, Marion
    Legendre, Christophe
    Anglicheau, Dany
    HUMAN IMMUNOLOGY, 2016, 77 (11) : 1055 - 1062
  • [6] Translating transplantation tolerance in the clinic: where are we, where do we go?
    Goldman, M.
    Wood, K.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 156 (02) : 185 - 188
  • [7] Translating tolerogenic therapies to the clinic - where do we stand?
    Issa, Fadi
    Wood, kathryn J.
    FRONTIERS IN IMMUNOLOGY, 2012, 3
  • [8] Selective Immune Apheresis Technologies - Where Do We Stand?
    Ramlow, Wolfgang
    Prophet, Heinrich
    Emmrich, Joerg
    PROGRESS AND CHALLENGES IN TRANSFUSION MEDICINE, HEMOSTASIS AND HEMOTHERAPY: STATE OF THE ART 2008, 2008, : 89 - +
  • [9] Pathology of heart transplantation: Where are we now?
    Rabant, Marion
    Coutance, Guillaume
    Isnard, Pierre
    Duong-Van-Huyen, Jean-Paul
    ANNALES DE PATHOLOGIE, 2021, 41 (01) : 38 - 49
  • [10] Assessment of Liver Graft Steatosis: Where Do We Stand?
    Cesaretti, Manuela
    Addeo, Pietro
    Schiavo, Luigi
    Anty, Rodolphe
    Iannelli, Antonio
    LIVER TRANSPLANTATION, 2019, 25 (03) : 500 - 509